R.A. Dent
- LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
2024/09/01 by P. Schmid, J. Cortés, R. Dent +24 · 1 citation
Medicine · #Cancer Immunotherapy and Biomarkers #Esophageal Cancer Research and Treatment #Lung Cancer Diagnosis and Treatment